Research
Current research, translated.
New studies on Type 2 Diabetes treatments — what they found and what they mean for the people taking these drugs. Plain-language up top, the full detail underneath.
Latest · Single-study breakdown
A glucose monitor helped people with type 2 diabetes who don't use insulin: what the CONNECT trial showed
In a 26-week trial in primary care, wearing a continuous glucose monitor lowered A1c by about 0.9 points more than usual care — without a new drug. What the NEJM study found, and what it can't tell you yet.
Single-study breakdown
Foundayo's ACHIEVE-4 heart-safety trial: as safe as insulin for the heart, with an early signal of fewer deaths
Evidence roundup
Semaglutide's big outcome trials: SELECT, FLOW, and SOUL explained
Single-study breakdown
The single amino acid that may explain GLP-1 drugs' longer-term effects on beta cells
Regulatory news
Orforglipron gains UK regulatory approval for type 2 diabetes
Evidence roundup
ADA 2026: the next wave of diabetes and obesity drugs, explained
Evidence roundup
Two new GLP-1 trials, one direction: what mazdutide and orforglipron mean together
Single-study breakdown
What the mazdutide obesity trial (GLORY-2) actually showed
Single-study breakdown
An oral GLP-1 added to insulin: what the orforglipron trial actually showed